Screening for prostate cancer decreases the risk of developing metastatic disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)

European Urology

Volumn 62, Issue 5, 2012, Pages 745-752

  Schröder, Fritz H ^a   Hugosson, Jonas ^b   Carlsson, Sigrid ^b   Tammela, Teuvo ^c   Määttänen, Liisa ^d   Auvinen, Anssi ^e   Kwiatkowski, MacIej ^f   Recker, Franz ^f   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

^e UNIVERSITY OF TAMPERE   (Finland)

^f NONE   (Switzerland)

Author keywords

Mass screening; Neoplasm metastases; Prostatic neoplasm

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORBIDITY; NETHERLANDS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SWEDEN; SWITZERLAND;

EARLY DETECTION OF CANCER; EUROPE; HUMANS; INCIDENCE; KALLIKREINS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84867059222     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.05.068     Document Type: Article

References (11)

1. F.H. Schröder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
2. F.H. Schröder, J. Hugosson, and M.J. Roobol Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
3. J. Hugosson, S. Carlsson, and G. Aus Mortality results from the Göteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
4. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
5. G. Aus, S. Bergdahl, P. Lodding, H. Lilja, and J. Hugosson Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial Eur Urol 51 2007 659 664
6. M.R. Cooperberg, J.M. Broering, and P.R. Caroll Risk assessment for prostate cancer metastases and mortality at the time of diagnosis J Natl Cancer Inst 101 2009 878 887
7. R. Etzioni, R. Gulati, S. Falcon, and D.F. Penson Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modelling approach Med Decis Making 28 2008 323 331
8. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease Actas Urol Esp 35 2011 501 514
9. O.O. Aalen Nonparametric inference for a family of counting processes Ann Stat 6 1978 701 726
10. T.P. Kilpeläinen, A. Auvinen, and L. Määttänen Results of the three rounds of the Finnish Prostate Cancer Screening Trial - the incidence of advanced cancer is decreased by screening Int J Cancer 127 2010 1699 1705
11. M.J. Roobol, E.W. Steyerberg, and R. Kranse A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer Eur Urol 57 2010 79 85